Car T-cell therapy for advanced pancreatic, breast, or sarcoma cancers
Part of Brain & nervous system, Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental cell therapy (CAR T-cells) for people with advanced pancreatic cancer, sarcoma, or breast cancer that has not responded to standard treatments. It may be an option if you have tried other therapies and are looking for a new approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old (for sarcoma) or over 18 (for pancreatic or breast cancer).
- You have been diagnosed with pancreatic cancer, sarcoma, or breast cancer.
- Your cancer has spread and you have already tried certain standard treatments, such as chemotherapy or targeted therapy, and it did not work or you could not tolerate it.
- You are willing to sign a consent form and use barrier contraception (like condoms) during the treatment and for 6 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests a special type of immune cell (called a CAR T-cell) that is trained to attack sarcoma cells. It is for children, teens, and young adults up to age 40 whose sarcoma has not responded to standard therapy. The treatment is given directly into the tumor, and the goal is to see if it is safe and how well it works.
This trial tests a new treatment called GCAR1, which uses your own immune cells (T-cells) to find and attack cancer cells that have a specific marker called GPNMB. It is for people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if this therapy can help shrink or control the tumor.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.